Tuoling Laparoscopic Surgical Robot
The Tuoling® Laparoscopic Surgical Robot (YC100) represents Tuodao Medical’s expansion into the high-value laparoscopic robotics market. Receiving NMPA approval in 2025, the system completed multi-center registration clinical trials across three surgical specialties in 2024, establishing Tuodao as a multi-platform surgical robotics company.
Product Overview
Tuoling® (佗灵, meaning “healing spirit”) enters a competitive domestic laparoscopic robot market alongside established players including MicroPort MedBot’s Toumai, Edge Medical’s MP1000, and the locally manufactured da Vinci system from Intuitive Fosun. The system is designed for minimally invasive procedures in urology, gynecology, and general surgery—the core applications that drive laparoscopic robot utilization.
The product development timeline moved rapidly from first complex urological surgery clinical trial case in March 2024 to completion of registration clinical trials across all three specialty areas by July 2024. This accelerated timeline enabled NMPA approval in early 2025.
Key Features
Approved by NMPA in 2025 after multi-center registration trials, Tuodao Medical’s Tuoling® covers urology, gynecology, and general surgery laparoscopic procedures on a single endoscopic surgical platform.
- Multi-specialty coverage: Single platform addresses urology, gynecology, and general surgery
- Endoscopic surgical system architecture: Designed for minimally invasive abdominal and pelvic procedures
- Clinical validation: Multi-center registration trials completed across three surgical specialties
Clinical Applications
Urology
The system’s clinical development program included complex urological procedures, with trial initiation in March 2024. Typical robotic urology applications include prostatectomy, partial nephrectomy, and pyeloplasty, though specific approved indications should be confirmed with the manufacturer.
Gynecology
Gynecological applications represent a significant portion of laparoscopic robot utilization globally. The Tuoling system completed gynecology clinical trials as part of its 2024 registration program.
General Surgery
General surgery applications may include cholecystectomy, hernia repair, and colorectal procedures, expanding the potential utilization of hospital robot installations beyond specialty-specific cases.
Regulatory Status
| Region | Status | Date |
|---|---|---|
| China (NMPA) | Approved | 2025 |
| Europe (CE) | Not Applied | - |
| United States (FDA) | Not Applied | - |
Development Timeline
- March 2024: First complex urological surgery clinical trial case completed
- July 2024: Registration clinical trials completed for urology, gynecology, and general surgery
- September 2024: Debut at Chinese Urological Association (CUA) Annual Meeting
- 2025: NMPA market approval received
Market Context
The Chinese laparoscopic surgical robot market has evolved significantly since domestic companies began commercializing alternatives to the da Vinci system. According to industry analysis, 2024 saw laparoscopic robots representing approximately 74.9% of the domestic surgical robot market by value. However, the segment has also experienced pricing pressure and intensified competition.
Tuodao’s entry with Tuoling positions the company to offer a broad surgical robot portfolio spanning orthopedic, percutaneous, and laparoscopic applications—a portfolio breadth matched by few domestic competitors.
Frequently Asked Questions
What specialties can use Tuoling?
Tuoling received NMPA approval for urology, gynecology, and general surgery applications, based on registration clinical trials completed across all three specialties in 2024.
How does Tuoling compare to other Chinese laparoscopic robots?
Tuoling enters a market with several established domestic competitors including MicroPort MedBot’s Toumai and Edge Medical’s MP1000. Detailed comparative specifications and clinical data would be needed for direct comparison. Tuodao’s differentiation may come from its ability to offer multiple robot platforms (orthopedic, percutaneous, laparoscopic) to hospital customers.
When did Tuoling receive approval?
Tuoling (YC100) received NMPA approval in 2025, following completion of registration clinical trials in July 2024.
Browse related categories
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.